Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years
This study provides valuable insights into the profile of patients treated with brodalumab in Canada. While the rapid and sustained skin clearance, as well as improvements in PASI, BSA, and DLQI scores, support the therapeutic benefits of brodalumab beyond clinical trials, further research on long-term effectiveness and safety is warranted.
Authors
- Dusan Sajic
- Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
- Belinda Yap (ORCID: https://orcid.org/0000-0001-7792-2474)
- V. Gaudet (ORCID: https://orcid.org/0000-0002-1285-7453)
- Maxime Barakat (ORCID: https://orcid.org/0000-0002-3000-2125)
- Vimal H. Prajapati (ORCID: https://orcid.org/0000-0002-8315-2522)
- Irina Turchin (ORCID: https://orcid.org/0000-0001-8654-9050)
- Virginie Kelly (ORCID: https://orcid.org/0000-0002-4580-4286)
- Shazia Hassan (ORCID: https://orcid.org/0000-0002-3040-9988)
Institutions
- Health Canada (CA)
- Dalhousie University (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- SKiN Health (CA)
- Lynde Centre for Dermatology (CA)
- Bausch Health (Canada) (CA)
- Probity Medical Research (CA)
- McMaster University (CA)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1007/s13555-025-01369-3
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.80